Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
Yoshinari Shinsato(Kagoshima University), Kazunori Arita(Kagoshima University)
Cited by 78
Related Papers
High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme
|British Journal of Cancer|2019|46
Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report
|Molecular and Clinical Oncology|2017|4